Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 3
1962 1
1969 1
1983 2
1984 1
1985 2
1987 1
1988 2
1989 1
1990 1
1991 1
1993 1
1994 5
1995 4
1996 5
1997 4
1998 17
1999 3
2000 8
2001 4
2002 5
2003 10
2004 7
2005 9
2006 11
2007 9
2008 4
2009 11
2010 13
2011 12
2012 3
2013 12
2014 13
2015 8
2016 7
2017 9
2018 10
2019 11
2020 14
2021 31
2022 35
2023 32
2024 32
2025 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

372 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
Inflammatory bowel disease genomics, transcriptomics, proteomics and metagenomics meet artificial intelligence.
Cannarozzi AL, Latiano A, Massimino L, Bossa F, Giuliani F, Riva M, Ungaro F, Guerra M, Brina ALD, Biscaglia G, Tavano F, Carparelli S, Fiorino G, Danese S, Perri F, Palmieri O. Cannarozzi AL, et al. Among authors: perri f. United European Gastroenterol J. 2024 Dec;12(10):1461-1480. doi: 10.1002/ueg2.12655. Epub 2024 Aug 31. United European Gastroenterol J. 2024. PMID: 39215755 Free PMC article. Review.
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer.
Ferrari M, Mularoni F, Smussi D, Gaudioso P, Bonomo P, Friborg J, Ghi MG, Gregoire V, Harrington K, Hunter K, Maroldi R, Martino R, Mesia R, Peretti G, Psyrri A, Schindler A, Succo G, Szturz P, Vilaseca I, Nicolai P, Bossi P; Consensus Group for Laryngeal Preservation. Ferrari M, et al. Lancet Oncol. 2025 May;26(5):e264-e281. doi: 10.1016/S1470-2045(25)00020-8. Lancet Oncol. 2025. PMID: 40318658 Review.
High- versus low-dose proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding: a multicentre, randomized study.
Andriulli A, Loperfido S, Focareta R, Leo P, Fornari F, Garripoli A, Tonti P, Peyre S, Spadaccini A, Marmo R, Merla A, Caroli A, Forte GB, Belmonte A, Aragona G, Imperiali G, Forte F, Monica F, Caruso N, Perri F. Andriulli A, et al. Among authors: perri f. Am J Gastroenterol. 2008 Dec;103(12):3011-8. doi: 10.1111/j.1572-0241.2008.02149.x. Am J Gastroenterol. 2008. PMID: 19086953 Clinical Trial.
Focus on Achalasia in the Omics Era.
Di Brina ALP, Palmieri O, Cannarozzi AL, Tavano F, Guerra M, Bossa F, Gentile M, Merla A, Biscaglia G, Cuttitta A, Perri F, Latiano A. Di Brina ALP, et al. Among authors: perri f. Int J Mol Sci. 2024 Sep 21;25(18):10148. doi: 10.3390/ijms251810148. Int J Mol Sci. 2024. PMID: 39337632 Free PMC article. Review.
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Fayette J, Licitra L, Harrington K, Haddad R, Siu LL, Liu YC, Tahara M, Machiels JP, Rischin D, Seiwert TY, Ferris RL, Keilholz U, Psyrri A, Keam B, Bossi P, Metcalf R, Hsieh CY, Clement PMJ, Isaev P, Mudunov A, Dinis J, Hoeben A, Kasper S, Klinghammer K, Hwang M, Blando J, Serrano O, Ruscica D, Cohen RB; INTERLINK-1 investigators. Fayette J, et al. Clin Cancer Res. 2025 Jul 1;31(13):2617-2627. doi: 10.1158/1078-0432.CCR-25-0073. Clin Cancer Res. 2025. PMID: 40300079 Free PMC article. Clinical Trial.
Social Media Advice for Dermatologists.
Borg JA, Chhoeung S, Georgiou DN, Hau BNC, Gayan TAK, Latifi S, Perri F, Petrovski M, Sertic AM, Velasquez SET. Borg JA, et al. Among authors: perri f. Skinmed. 2024 Oct 22;22(5):340-345. eCollection 2024. Skinmed. 2024. PMID: 39433516
N-methyl-N-nosyl-beta(3)-amino acids.
Belsito E, Di Gioia ML, Greco A, Leggio A, Liguori A, Perri F, Siciliano C, Viscomi MC. Belsito E, et al. Among authors: perri f. J Org Chem. 2007 Jun 22;72(13):4798-802. doi: 10.1021/jo070438i. Epub 2007 Jun 1. J Org Chem. 2007. PMID: 17539685
Clinical and genetic drivers of oligo-metastatic disease in colon cancer.
Ottaiano A, Santorsola M, Sirica R, Mauro AD, Di Carlo A, Ianniello M, Sabbatino F, Castiello R, Peschio FD, Cascella M, Perri F, Capuozzo M, Martucci N, Mercadante E, Borzillo V, Di Franco R, Izzo F, Granata V, Picone C, Petrillo A, Berretta M, Stilo S, Tarotto L, Carratù AC, Ferrara G, Tathode M, Cossu AM, Bocchetti M, Caraglia M, Nasti G, Savarese G. Ottaiano A, et al. Among authors: perri f. Neoplasia. 2025 Feb;60:101111. doi: 10.1016/j.neo.2024.101111. Epub 2024 Dec 21. Neoplasia. 2025. PMID: 39709701 Free PMC article.
372 results